Vir Biotechnology (VIR) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary

Strategic priorities and milestones for 2025

• Focus on infectious diseases and oncology, leveraging immune system engagement for patient impact.

• Registrational trials for hepatitis Delta to begin in the first half of 2025, following strong virological and ALT normalization data.

• Hepatitis B program will assess functional cure rates in Q2 2025, guiding next steps based on six-month post-treatment data.

• Oncology efforts include a partnership with Sanofi, advancing three clinical-stage T-cell engagers targeting HER2, PSMA, and EGFR.

• Initial data from HER2 and PSMA programs to be shared at an investor event in January, with EGFR program dosing to start in H1 2025.

Hepatitis Delta program and competitive landscape

• Combination therapy with tobevibart and siRNA shows significant Delta RNA reductions and ALT normalization, with up to 80% target not detected at week 60.

• Monthly dosing regimen offers greater convenience compared to daily standard of care, with strong safety profile and efficacy in both cirrhotic and non-cirrhotic patients.

• ECLIPSE 1, 2, and 3 trials designed to address diverse patient populations and regulatory requirements across geographies.

• Fast Track designation in the US and Orphan Drug Designation in Europe secured; Breakthrough and PRIME designations being pursued.

• Competitive differentiation based on deep and rapid viral decline, immune engagement, and robust safety, with regulatory engagement ongoing.

Hepatitis B program outlook

• 48-week end-of-treatment data show 39% S-antigen loss with doublet and 46% with triplet therapy in patients with low baseline S-antigen.

• Strong correlation observed between S-antigen loss and antibody generation, indicating potential for functional cure.

• Q2 2025 data will determine functional cure rates, with 20–30% considered a meaningful benchmark.

• Next steps may include large phase III trials and potential partnership, depending on upcoming data.